ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
äŒæ¥ã³ãŒãNDRA
äŒç€ŸåENDRA Life Sciences Inc
äžå Žæ¥Jun 28, 2017
æé«çµå¶è²¬ä»»è
ãCEOãTokman (Alexander Y)
åŸæ¥å¡æ°21
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 28
æ¬ç€Ÿæåšå°3600 Green Ct Ste 350
éœåžANN ARBOR
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·48105
é»è©±çªå·17343350468
ãŠã§ããµã€ãhttps://www.endrainc.com/
äŒæ¥ã³ãŒãNDRA
äžå Žæ¥Jun 28, 2017
æé«çµå¶è²¬ä»»è
ãCEOãTokman (Alexander Y)